Unity Biotechnology Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Unity Biotechnology ha un patrimonio netto totale di $14.1M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $47.1M e $33.0M.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	n/a
Contanti	US$29.04m
Patrimonio netto	US$14.14m
Totale passività	US$32.99m
Totale attività	US$47.13m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $30.3M ) di 9U9 superano le sue passività a breve termine ( $8.8M ).

Passività a lungo termine: Le attività a breve termine di 9U9 ( $30.3M ) superano le sue passività a lungo termine ( $24.2M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 9U9 è esente da debiti.

Riduzione del debito: 9U9 non aveva debiti 5 anni fa.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: 9U9 ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: 9U9 ha una liquidità sufficiente per 1 anni se il flusso di cassa libero continua a crescere ai tassi storici del 13.6 % ogni anno.

Unity Biotechnology Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Unity Biotechnology, Inc. announced delayed annual 10-K filing

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

Recent updates

New minor risk - Share price stability

UNITY Biotechnology, Inc. Announces the Appointment of Alicia Tozier as Chief Strategy Officer

Insufficient new directors

Unity Biotechnology, Inc., Annual General Meeting, Jun 21, 2024

Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME

Unity Biotechnology, Inc. announced delayed annual 10-K filing

Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss

Insufficient new directors

Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME

New major risk - Financial position

UNITY Biotechnology, Inc. Announces 48-Week Results from Phase 2 Envision Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

New major risk - Revenue and earnings growth

Unity Biotechnology, Inc. Announces Design of Phase 2B Aspire Study Evaluating Ubx1325 in Diabetic Macular Edema (Dme)

Unity Biotechnology, Inc. Announces Positive 24-Week Data from Phase 2 Behold Study of UBX1325 in Patients with Diabetic Macular Edema

Unity Biotechnology, Inc. Completes Enrollment in Phase 2 Envision Study of UBX1325 in Wet Age-Related Macular Degeneration

Unity Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.

Unity Biotechnology Announces Positive Data in Phase 2 Behold Study of Ubx1325 in Patients with Diabetic Macular Edema

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

UNITY Biotechnology Announces Board Changes

UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases

Unity Biotechnology, Inc., Annual General Meeting, Jun 24, 2022

UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular Degenera

Unity Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema

Kristina Burow Resigns as Member of the Board and All of the Committees of the Board from Unity Biotechnology, Inc

Unity Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease

Unity Biotechnology, Inc. Announces the Design for Its Phase 2 Study of Ubx1325 in Wet Age-Related Macular Degeneration and Anticipated Milestones for 2022

Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell 3000E Index

UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseases

Unity Biotechnology, Inc. Announces Impairment of Long Lived Assets for the Three Months Ended December 31, 2020

Unity Biotechnology, Inc. Appoints Alexander Nguyen as General Counsel

Unity Biotechnology, Inc. Announces New Preclinical Research That Reveals A Novel Mechanism for Treating Age-Related Eye Diseases

New 90-day high: €6.20

Unity Biotechnology, Inc. Appoints Przemyslaw (Mike) Sapieha as Chief Scientific Advisor

New 90-day high: €5.29

Unity Biotechnology Announces Executive Changes

New 90-day high: €4.03

Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema

New 90-day low - €2.48

New 90-day high - €10.22

Unity Biotechnology, Inc. announced that it expects to receive $80 million in funding from Hercules Capital, Inc.

Unity Biotechnology, Inc. to Report Q2, 2020 Results on Jul 31, 2020

Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell Microcap Value Index

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane